RAC1 and neoplasm: Unlike previous studies that relied on ectopic overexpression of mutant RAC1 (29–31), the knock-in mutant allows the investigation of effects by an endogenous RAC1 mutation that better mimics the pathophysiological condition of the tumor cells.